🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Health-tech startup Dectrocel raises Rs 4 Cr led by IAN Group-backed BoiAngels

EntrackrEntrackr · 2d ago
Health-tech startup Dectrocel raises Rs 4 Cr led by IAN Group-backed BoiAngels
Medial

Dectrocel, a health-tech startup developing AI-powered diagnostic solutions, has raised Rs 4 crore in a funding round led by IAN Group-powered BioAngels along with participation from PadUp Ventures and Vinners. The proceeds will be used to scale its commercial operations across India, enhance AI technology, expand into international markets, and accelerate the launch of new AI tools in CT/MRI/PET-CT and HPB diagnostic modules. Co-founded in 2020 by Ankit Shukla, Saumya Shukla, and Nikhil Mishra, Dectrocel's flagship product, DecXpert, delivers chest X-ray and CT-scan interpretations, is one of only three AI-based diagnostic tools approved for clinical use in India, and claims it is 10x faster with 98% accuracy. Dectrocel aims to bridge the diagnostic gap caused by a shortage of radiologists in India, particularly in smaller cities, by providing quality diagnostics equivalent to those in metro hospitals. The company plans to expand its commercial deployment across OEM partner networks, penetrate the Rs 1,000 crore digital X-ray market, and establish an initial presence in Southeast Asia.

5

Related News

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 2m ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Perkant Tech raises Rs 6.6 Cr in seed round

EntrackrEntrackr · 5m ago
Perkant Tech raises Rs 6.6 Cr in seed round
Medial

Perkant Tech raises Rs 6.6 Cr in seed round Indore-based health tech startup Perkant Tech has raised Rs 6.6 crore ($771K) in its seed round led by YourNest Venture Capital. The funding also saw support from the Government of India’s Atal New India Challenge (Rs 1 crore), Villgro Foundation (Rs 35 lakh), and Sanchi Connect (Rs 25 lakh). The proceeds will be used to help Perkant Tech improve its technology, grow its team, and prepare for a wider launch after successful tests. The firm also plans to add more features for detecting diseases early and helping in recovery tracking. Founded in 2020 by engineers Lokant Jain and Saniya Jeswani, Perkant Tech has created a smart AI-powered medical device that gives quick and clear health checks. Its main product, “Abhay Parimiti,” can scan a person’s health in under 60 seconds and works even in areas with limited doctors. Perkant’s technology is already patented in India and has a pending patent in the U.S. It is also aligned with India’s National Digital Health Mission. Its system can track over 700 body signals, helping people stay ahead of serious illnesses. The device is easy to use, making it helpful for both doctors and non-medical users in rural or remote places.

Ambulance startup Dial4242 raises Rs 9 Cr in pre-Series A round

EntrackrEntrackr · 1m ago
Ambulance startup Dial4242 raises Rs 9 Cr in pre-Series A round
Medial

Ambulance tech startup Dial4242 has raised Rs 9 crore (around $1.04 million) in its pre-Series A funding round led by IAN Group, with participation from BioAngels, IIM Bangalore’s NSRCEL, and other notable angels. Earlier in September 2023, Dial4242 had raised Rs 1 crore in its seed round led by investors G Vamshi Raju, Starfish Ventures, and a clutch of angel investors based in Hyderabad. The proceeds will be used to scale operations, improve ambulance turnaround time from 12 to under 8 minutes, expand medical centers in underserved areas, strengthen tech infrastructure, and boost leadership hiring. Founded in 2016 by Jeetendra Lalwani, Nilesh Mahambre, and Atin Verma, Dial4242 runs a tech-enabled ambulance network in India, covering over 850 cities. Its platform enables real-time tracking, automated dispatch, and 24x7 emergency coordination. With a tech-first, asset-light model, the startup has partnered with firms like Amazon, Zomato, and Swiggy to provide emergency care access to gig workers. The brand also plans to launch a low-cost membership model offering free ambulance access, deepen hospital partnerships, and further improve emergency response standards. Dial4242 competes with the likes of MeduLance, HelpNow, ESahai, AmbiPalm and Mo Ambulance among others in the ambulance booking segment.

Allo Health raises Rs 16 Cr in pre-Series A round

EntrackrEntrackr · 6m ago
Allo Health raises Rs 16 Cr in pre-Series A round
Medial

Allo Health raises Rs 16 Cr in pre-Series A round Sexual health startup Allo Health has raised Rs 16 crore ($1.83 million) in its pre-Series A round led by Rainmatter along with existing investors. Prior to this round, Allo had raised $4.4 million in seed funding led by Nexus Venture Partners, with participation from founders and operators, including Binny Bansal (Flipkart), Deepinder Goyal (Zomato), Rohit MA (Cloudnine), and Sandeep Singhal (Nexus). The proceeds will be used to ramp up clinic densification, invest in deeper technology capabilities, and enhance patient engagement as Allo continues to scale. Founded by Pranay Jivrajka, Allo has built a hybrid ecosystem that combines physical clinics, AI-powered treatment protocols, and trained medical professionals. Allo’s proprietary doctor training programs, AI-powered clinical decision support, and research-backed treatment helps it manage effectively. Since its inception, Allo claims to have treated over 200,000 patients across India, achieving a 85% improvement in patient outcomes, with over 35 clinics across major cities, including Bangalore, Mumbai, Pune, Hyderabad, Chennai, Mysore, and Ranchi.

Men’s health startup RxMen raises Rs 5 Cr in seed round led by IPV

EntrackrEntrackr · 5d ago
Men’s health startup RxMen raises Rs 5 Cr in seed round led by IPV
Medial

RxMen, a Delhi-based men’s health tech startup, has raised Rs 5 crore (around $570K) in its seed round led by Inflection Point Ventures (IPV). The round also saw participation from SPA Family Ventures, Ankit Goel, Seven Square Ventures, along with a grant from Prosus Group. The proceeds will be used for brand building, launching RxMen-branded products, and setting up co-branded clinics. The firm targets to achieve positive EBITDA by October 2025. Founded in 2023 by Shailja Mittal, RxMen is a full-stack, clinic-led men’s health platform. It focuses on root-cause treatment across sexual health, hormones, skin, stress, and sleep. Over the past 20 months, RxMen claims to have grown 100x in revenue and reported an MRR of $70,000 (Aug 2025), with an ARR projection of $1.7 million by FY26. It has delivered over 30,000 consultations and is handling 6,000 consultations monthly through a network of 30 specialists in urology, psychiatry, sexology, and therapy. RxMen has developed a Sexual Health Index (SHI), now under validation at IIT Jodhpur, built from 25,000 anonymized consultations. It reports a 95% success rate based on SHI outcomes. It will compete with Man Matters (Mosaic Wellness), Bold Care, and Traya.

Sunfox Technologies raises Rs 15 Cr led by Venture Catalysts

EntrackrEntrackr · 1y ago
Sunfox Technologies raises Rs 15 Cr led by Venture Catalysts
Medial

Health-tech startup Sunfox Technologies has secured Rs 15 crore in a pre-Series A funding round led by Venture Catalysts along with participation from Finvolve through the IA Growth Opportunities Fund I and Brew Opportunities Fund, as well as Universal Group, RP Singhvi Group, and others. The company had previously raised Rs 5 crore investment from USAID through SAMRIDH Health and LetsVenture. It was also featured in Shark Tank India. The fresh funds will be used for expansion in India and globally and focus on scaling its flagship innovation Spandan, Sunfox stated in a press-release. Co-founded in 2016 by Rajat Jain, Arpit Jain, Saurabh Badola, Nitin Chandola, and Sabit Rawat, Sunfox is an R&D lab which aims to develop cutting-edge healthcare technologies for the digital world. Its flagship product Spandan is a smartphone-based portable ECG device that provides clinically accurate 12-lead ECG readings, empowering users to detect heart attacks and monitor cardiac health in real-time. The Dehradun-based claims that Spandan has been used by over 30,000 individuals across 20 countries and saved more than 10,000 lives through early detection of heart conditions. This technology is proving critical as India confronts a surge in heart attacks post-COVID-19. Sunfox has established an advanced in-house R&D and manufacturing facility in Dehradun and even captured global attention from prestigious institutions such as Oxford and Wharton.

Genexis Biotech raises Rs 4 Cr in seed round led by GVFL

EntrackrEntrackr · 1m ago
Genexis Biotech raises Rs 4 Cr in seed round led by GVFL
Medial

Genexis Biotech raises Rs 4 Cr in seed round led by GVFL Vadodara-based bio-manufacturing startup Genexis Biotech has raised Rs 4 crore in a seed funding round led by GVFL, with participation from Benzai10. The proceeds will be used to scale bioreactor capacity, build downstream processing infrastructure, launch new recombinant proteins and enzymes, and strengthen compliance, sales, and distribution functions. Genexis Biotech develops animal-origin-free recombinant proteins using precision fermentation, catering to sectors like biopharma, food-tech, and cell culture. The startup operates a certified Class 10,000 facility and is setting up a GMP-compliant unit. It has introduced recombinant peptidases such as amino peptidase and enterokinase, and plans to launch recombinant transferrin and albumin. In the past year, Genexis established partnerships with pharmaceutical companies and biotech firms, signed an MoU with the Gujarat government, and received client orders for alternative protein formulations. It showcased its portfolio at Global Bio-India 2024 and aims to enter the regulated biotech export market, develop encapsulated formulations for the cosmetics industry, and collaborate with CDMOs, academic labs, and biopharma firms. Genexis Biotech focuses on scalable, ethical biomolecule production. GVFL has backed the company as part of its investment thesis across deeptech and biotech innovation.

Download the medial app to read full posts, comements and news.